10.1016/j.npep.2018.07.003 168
This calls for more extensive research to unravel the intricate relationships between the GLP-1R agonist and different cancers, providing valuable insights for clinicians and researchers alike
It is a drug part of the glucagon-like-peptide 1 receptor antagonists, or GLP-1 receptor antagonist family, that when specifically used for treating weight loss, acts on GLP-1 receptors in the brain, on top of the liver, pancreas, and stomach
The decision tree: matching drug names to your treatment goal Use this decision tree to identify which GLP-1 medication class aligns with your treatment goal
GLP-1 Addiction Reduction Evidence in Rodents and Primates Randomized controlled trials in mice, rats, and monkeys have shown strong anti-addiction effects from GLP-1RAs